You are on page 1of 18

Clinical Epidemiology

open access to scientific and medical research


Open Access Full Text Article

The worldwide epidemiology of acute rheumatic
fever and rheumatic heart disease
This article was published in the following Dove Press journal:
Clinical Epidemiology
22 February 2011
Number of times this article has been viewed

Michael D Seckeler
Tracey R Hoke
Department of Pediatrics, Division
of Cardiology, University of Virginia,
Charlottesville, VA, USA

Abstract: Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) are significant
public health concerns around the world. Despite decreasing incidence, there is still a significant
disease burden, especially in developing nations. This review provides background on the
history of ARF, its pathology and treatment, and the current reported worldwide incidence of
ARF and prevalence of RHD.
Keywords: rheumatic fever, rheumatic heart disease, group A streptococcus, epidemiology

Acute rheumatic fever (ARF) is a postinfectious, nonsuppurative sequela of pharyngeal
infection with Streptococcus pyogenes, or Group A β hemolytic Streptococcus
(GABHS). Of the associated symptoms, only damage to the valve tissue within the
heart, or rheumatic heart disease (RHD), can become a chronic condition leading to
congestive heart failure, strokes, endocarditis, and death. While the incidence and
prevalence of ARF and RHD have been decreasing in developed nations since the
early 1900s, they continue to be major causes of morbidity and mortality among young
people in developing nations. It is estimated that there are over 15 million cases of
RHD worldwide, with 282,000 new cases and 233,000 deaths annually.1
More recent data using echocardiography to screen for RHD in developing nations
have lead to a marked increase in the recognized prevalence in these regions.2–6
With these new data, there has been an increased awareness and interest in ARF and
RHD, which stimulated this review of the literature to provide information on the
pathogenesis, diagnosis, and treatment for ARF and RHD, and an updated estimate
of the worldwide incidence and prevalence.


Correspondence: Michael D Seckeler
PO Box 800386, University of Virginia,
Charlottesville, VA 22908, USA
Tel +1 (434) 924-9119
Fax +1 (434) 924-5656
submit your manuscript |


Although physicians in Europe had been describing clinical components of ARF since
the 1500s, it was William Charles Wells’ seminal publication in 1812 that definitively
linked ARF with carditis.7 The entire clinical spectrum of ARF (from tonsillitis to
carditis) was first described by Cheadle in 1889.8 The infectious etiology of ARF was
long suspected, especially given the seasonal variation in outbreaks, and in 1900 Poynton
and Paine described a diplococcus isolated from patients with ARF, which they implicated as a causal organism for the disease.9 Micrococcus (or Streptococcus) rheumaticus
was isolated from a patient with ARF in 1904, and was noted to be “indistinguishable
from strains of Streptococcus pyogenes”.10 Into the 1930s, theories implicating viruses
as causal agents for ARF surfaced,11 and are still being investigated today.12,13
Clinical Epidemiology 2011:3 67–84
© 2011 Seckeler and Hoke, publisher and licensee Dove Medical Press Ltd. This is an Open Access article
which permits unrestricted noncommercial use, provided the original work is properly cited.

18 The Minor criteria are arthralgias. These markers can also be followed as signs of resolution of ARF.16 1984.19. Fever. Sydenham chorea. Having first degree heart block does not predict whether a patient will develop RHD. elevated acutephase reactants. There can also be worsening school performance.14 This year was used as a cutoff to create 2 eras: 1970 through 1990. uncontrolled movements of the trunk or extremities. joints that can change from one location to another as the disease progresses. Arthralgia is pain. Carditis is typically valvulitis and has traditionally been diagnosed by a new murmur suggestive of valvar regurgitation. These data were plotted for the time period 1970 to 2009.18 There has been controversy over the use of Doppler echocardiography in the diagnosis of ARF. Subcutaneous nodules are painless. C-reactive protein. 68 submit your manuscript | www. both of which are expected to be elevated during an episode of ARF. Vitus’ dance. erythema marginatum. Regional incidence and prevalence estimates were not weighted by the underlying population. and Western Pacific. is rapid. Clinical Epidemiology 2011:3 . and first degree heart block. Diagnosis The diagnostic criteria for ARF were first developed by Jones in 194415 and have since been modified in 1965. Sydenham chorea. a patient can have either arthritis or arthralgia as a Jones criterion. usually large. often in multiple joints. either by a pharyngeal swab culture positive for GABHS. serpiginous (snake-like) borders found on the trunk and extremities.20 Many argue Table 1 Major and Minor Jones criteria for the diagnosis of acute rheumatic fever18 Major criteria Minor criteria Migratory polyarthritis Carditis Erythema marginatum Syndenham chorea Subcutaneous nodules Arthralgia Fever First degree heart block Elevated inflammatory markers (ESR. To generate trends of ARF incidence and RHD prevalence over time. Acute-phase reactants are nonspecific laboratory markers of inflammation in the body. and trend lines were calculated with quadratic regression for each WHO region and are reported in the graphs. The last major WHO report on the worldwide prevalence of ARF and RHD reported data through 1990. fleshcolored bumps. or St.Dovepress Seckeler and Hoke Methods An extensive literature search for any articles about “acute rheumatic fever” or “rheumatic heart disease” was performed in August 2010 using PubMed. and intense pain of multiple. plus evidence of recent streptococcal infection. is common in early ARF. data from various countries were clustered by World Health Organization (WHO) region – Africa. usually at least 39°C. ARF incidence and RHD prevalence rates for each reporting country during these eras were graded and plotted on a world map to show the changes in disease burden and geographic location with time in more detail than the trend plots. Data reported from any countries within a WHO region for a given year were averaged together to provide a value for that year. and 1991 through the present.18 and 2002. There may be myocarditis or pericarditis in addition to the valvulitis. Europe. Of note. swelling.19 The criteria are divided into Major and Minor criteria (Table 1). but echocardiography has been used more in recent years to aid in the diagnosis (see below). The typical ones measured are erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).com Dovepress Figure 1 Electrocardiogram demonstrating first-degree heart block in a patient with acute rheumatic fever.dovepress. carditis. without associated redness or swelling. erythrocyte sedimentation rate. Eastern Mediterranean. the Americas. In order to maximize the available information. Jones criteria for each of the WHO regions were compared using one way ANOVA with post-hoc analysis to identify significant differences in criteria between regions.18 The Major criteria are migratory polyarthritis. Erythema marginatum is a transient rash with central pallor and red. ESR. Polyarthitis is redness. Articles reporting data of the incidence of ARF or prevalence of RHD were reviewed. Diagnosis is made by the presence of either 2 Major or 1 Major and 2 Minor criteria. positive rapid GABHS ­antigen test or rising serologic antibody titers (antistreptolysin O [ASO]. but not both.17 1992. The PR interval is noted by the arrows. usually found on the extensor surfaces of the arms and legs. DNAse B. CRP) Abbreviations: CRP. behavioral changes. or streptokinase). and subcutaneous nodules. fever. non-English language articles were included if it was possible to obtain an English translation of either the abstract or the entire article. First degree heart block is diagnosed by prolongation of the PR interval on electrocardiogram (Figure  1). Southeast Asia. and is markedly prolonged at 300 milliseconds (normal for an adult is less than 200 milliseconds). and emotional lability.

HLADR7 has been the most frequently associated with ARF and RHD. Patients that recover from the initial ­rheumatic carditis are likely to have permanent valve ­damage.51 Once heart valves have been damaged. these patients require medical ­management for their heart failure. there is concern for overdiagnosis of carditis by relying on Doppler echocardiography. tumor necrosis factor-α (TNF-α). then host cells can be attacked. the foreign antigen is the M-protein and it cross reacts with cardiac myosin. which can be the presenting symptom of ARF. and over time the affected valves can become stenotic in addition to regurgitant. especially among high-risk populations. host tissue without the continued need for streptococci to be present.30 This leads to further inflammation and scarring of heart valve tissue and chronic RHD. Once valve tissue is damaged and inflamed.47 These antibodies could subsequently react Dovepress 69 . and while there have been no universal associations.30 A third factor.25 ARF is believed to be an autoimmune reaction to GABHS infection.19 The current American Heart Association guidelines recommend the use of Doppler echocardiography as a supplement to diagnosis. and damage. binds to various sugar molecules on the cell surface and helps to mark foreign cells for immune cells to eliminate. If the HLA molecules present antigens that resemble both Streptococcus and human tissues. 50 Further study has led to the identification of the M-protein on the GABHS cell membrane as the likely antigen for inducing the production of antibodies that cross-react with human heart tissue. they do not function properly. or regurgitate. but only in the presence of killed streptococci. and subsequently demonstrated that anticardiac and ­antiskeletal muscle antibodies were produced in rats. TNF-α may be upregulated in patients with increased ARF susceptibility.26 Many studies have investigated the role of HLA alleles. and blood is allowed to leak backward. but evidence of valvar regurgitation should not be used as a Major or Minor criterion. this can cause acute congestive heart failure. and subsequent development of ARF.Dovepress that echocardiography can help to diagnosis subclinical RHD. RHD patients with mitral valve damage have been found to have high levels of MBL Clinical Epidemiology 2011:3 Epidemiology of rheumatic fever in their blood. which can then attack the antigen or activate B cells to produce antibodies to the antigen. In severe cases. Figure  2a shows normal cardiac anatomy and Figures  2b and 2c show echocardiograms demonstrating a thickened. which is also located on chromosome 6 near the HLA alleles. a clear understanding of the pathophysiology still eludes modern physicians.21–24 However. they should be equally susceptible to attack from an autoantibody. where all or part of a foreign antigen resembles at least some portion of host tissue. since it is not known how much valvar regurgitation is “normal”. All four heart valves can be involved in rheumatic carditis. which are located on chromosome 6. proteins that are normally intracellular can become exposed to invading immune cells and lead to the development of more autoantibodies directed at different component proteins of valve tissue. however there is a marked predominance of mitral valve involvement. Since all heart valves develop from the same tissue. This is called molecular mimicry and will be discussed more below. and has been supported by outbreaks of ARF following outbreaks of pharyngitis.27–45 While the exact mechanism by which certain genes can confer an increased susceptibility to ARF has not been delineated. regurgitant mitral valve. The role of GABHS infection as an initial event is clear. In addition to the usual treatment for ARF. Another protein that has been associated with ARF and RHD is the inflammatory cytokine.30 The theory of cross-reaction between GABHS and heart tissue has been explored for at least 60 years. leading to an increased inflammatory response in these patients. as well as rising antistreptococcal antibodies in patients with ARF. The cross-reactivity is believed to occur through molecular mimicry. In ARF and RHD. This has recently been associated with higher levels of MBL. HLA molecules process antigens within a host cell and present them on the cell surface to T cells. while those with aortic valve damage have low levels. Pathophysiology Even though ARF has been recognized as a disease entity for at least 150 years. Cavelti first identified anticardiac autoantibodies in ARF in 1945.30 but is not clear why more MBL leads to damage of the mitral valve.48 In 1962. Severe valve stenosis or ­regurgitation can eventually warrant surgical repair or replacement of submit your manuscript | www. especially given the tendency for outbreaks to occur within families and the relatively few cases of ARF that develop given the high prevalence of GABHS pharyngitis and pharyngeal carriage. in ARF susceptibility.dovepress. which induces T-cell mediated attack of the heart tissue and valves. mannose-binding lectin (MBL).46. Genetically determined host susceptibility has long been presumed. Kaplan and colleagues demonstrated a cross-reactivity between human heart tissue and GABHS 49 and later anticardiac antibodies in patients with ARF. there are theories about the roles played.

One of the ­earliest reports of brain MRI findings in acute ­Sydenham chorea demonstrated increased signal intensity in the caudate nucleus. or juvenile rheumatoid arthritis) among 261 North American patients from 1985 to 2005 found that 55% of the surgeries were for RHD (160 patients. and degenerative changes in ­recurrent chorea. 61 This appeared to ­correlate with pathologic findings seen in ­varying case series which show blood vessel inflammation. a component of the basal ganglia. speech and behavioral issues. neonatal lupus.62 Subsequent case series have ­demonstrated acute changes in the caudate nucleus (some of which progressed to cystic changes on subsequent studies)63 and others with lesions in the subcortical white matter. demonstrating the left atrium connected to the left ventricle via a mitral valve. Not only 70 submit your manuscript | www.60 One function of the basal ganglia is inhibition of motor impulses. which may be the cause of speech and behavioral symptoms. demonstrating a thickened anterior leaflet of the mitral valve.54–57 The cost of surgical intervention for RHD is approximately US$25. There appears to be molecular mimicry involved in the development of Syndeham chorea as well. ­neuronal pathways can be disrupted as well.64 Clinical Epidemiology 2011:3 . with mortality from endocarditis ranging from 29% to 36%. Numerous studies have provided evidence for anti-neuronal antibodies to the basal ganglia in patients with Sydenham chorea.58 Early detection of ARF and RHD through screening programs can reduce the morbidity of chronic RHD and surgeries for heart valve repair or replacement. but since gangliosides are involved in cell signaling. Investigators have used MRI to examine the brains of patients with Sydenham chorea to determine the ­etiology of the movement. Kawasaki disease. 200 procedures) with 3  in-hospital deaths.Seckeler and Hoke Dovepress Figure 2 a) Artist rendition of normal left heart anatomy.6% of Dovepress does this cause inflammation and damage neurons. Damage to this area can explain the unusual movements associated with Sydenham chorea. demonstrating moderate-to-severe mitral valve regurgitation (blue jet). which is enough to fund 1 year of an RHD screening program in a small developing nation.61.000. A recent review of 361 cardiac ­surgeries for rheumatic disease (RHD. with ­a ssociated edema and shifting of brain matter. systemic lupus.53 In various series of patients with endocarditis. c) Two-dimensional echocardiogram with color Doppler.52 b) Two-dimensional echocardiogram of the left heart.59 Kirvan and colleagues recently found a carbohydrate ­component of the streptococcal cell wall that cross-reacts with gangliosides in the cell membrane of neurons in the basal ganglia. RHD was the underlying cause in 15% to 76. the affected heart valves.dovepress. occlusion and necrosis in early disease.

including erythromycin.27 kg) 50 mg/kg by mouth daily Drug-dependent 10 days Benzathine penicillin G Amoxicillin Cephalosporina (first generation) Clindamycina Clarithromycina Azithromycina 20 mg/kg/day divided in 3 doses by mouth 15 mg/kg/day divided in 2 doses by mouth 12 mg/kg by mouth daily Once 10 days 10 days 10 days 10 days 5 days Notes: aIn penicillin-allergic patients. The first line is primary prevention through the recognition of GABHS pharyngitis and treatment with appropriate antibiotics. a single intramuscular dose of benzathine penicillin G (BPG) can be given at the time of GABHS pharyngitis diagnosis. and there are currently 4 vaccines in development targeting the M-protein. and azithromycin. but as many as 5% may also be allergic to cephalosporins. Source: American Heart Association. Inc. Note. Patients that have a hypersensitivity to penicillin may be treated with a first-generation cephalosporin. ­tetracyclines. While there are many potential vaccine candidates.66 Treatment Primary prevention There are several approaches to reduce the impact of ARF. and sulfonamides are not recommended to treat GABHS pharyngitis. clarithromycin. and there has never been documentation of GABHS isolates that are resistant to penicillin.66 Full details of antibiotic treatments for GABHS pharyngitis are shown in Table 2. are another alternative. Macrolides. For patients in whom compliance with an oral regimen is a problem.000 units intramuscular (.66 Oral penicillin V is still the first line treatment in patients whom compliance can be expected. Antibiotic therapy initiated within 9 days of onset of pharyngitis is effective in preventing ARF.Dovepress Epidemiology of rheumatic fever Table 2 Antibiotic regimens for treatment of group A streptococcal pharyngeal infections.68 Part of the complexity in vaccine development is the high ­variability Clinical Epidemiology 2011:3 Figure 3 Schematic drawing of the M-protein structure with the conserved (blue).27 kg) 600. Another intriguing area of research for the past 40 years in ARF prevention is GABHS vaccine Dovepress 71 . Note that the conserved region is closest to the cell membrane. although there have been GABHS strains that demonstrate macrolide resistance. up to 5% of patients allergic to penicillin may also be allergic to cephalosporins. submit your manuscript | www.65. Antibiotic Dose Duration Penicillin V 250 mg by mouth 2 to 3 times daily (#27 kg) or 500 mg by mouth 2 to 3 times daily (. Fluoroquinolones. the extracellular M-protein on the surface of GABHS cells has become the primary target.dovepress. variable (red).200. 67.000 units intramuscular (#27 kg) or 1.65. and hypervariable (green) regions.

the progression to degenerative changes seen in recurrent chorea makes corticosteroids less likely to be of any benefit in this group. naproxen has been used as an alternative anti-inflammatory agent. Secondary antibiotic prophylaxis is only effective when there is high compliance. usually 4 to 6 weeks.61. these can be equally effective.79 Given the higher likelihood of side effects from steroid treatment.21 Treatment with aspirin usually causes marked improvement in the joint manifestations of ARF within 24 to 48 hours. if they had not already. including irradiation of the heart.77 While aspirin has remained the mainstay of ARF therapy.70. Secondary prophylaxis Those patients who develop ARF are at high risk to develop subsequent attacks when infected with GABHS.73 Since then.Dovepress Seckeler and Hoke of the M-proteins. variable.81 Some groups do recommend the use of corticosteroids for carditis in patients who are in severe heart failure. However. and are likely to provide protection against a wider range of M-types. but 3 of 21 also developed ARF. They found that there was no difference in final outcomes. Table 3 Antibiotic regimen for secondary prophylaxis of acute rheumatic fever. The other three M-protein-based vaccines in development target the conserved region of the M-protein. ­Figure 3 shows a schematic of the structure of the M-protein. For those who cannot tolerate aspirin.78 A more recent meta-analysis confirmed these results and found no significant reduction in the development of RHD with corticosteroids compared to aspirin.5 g by mouth daily (#27 kg) or 1 g by mouth daily (. there is concern that vaccination could actually cause ARF.76 and prolonged confinement to a hyperoxic chamber. There have been studies showing decreased ­severity and duration of chorea with prednisone therapy. The hypervariable region is exposed to the host immune system and is the portion that distinguishes each M subtype. and found a quicker resolution of chorea symptoms in the treatment group. people living in crowded conditions Clinical Epidemiology 2011:3 .84 If patients are compliant with oral regimens.83 so many healthcare providers prescribe intramuscular BPG every 4 weeks to ensure adequate serum penicillin levels.66 72 submit your manuscript | www. This has prompted the study of other anti-inflammatory medications.82 Paz and colleagues82 performed a placebo-controlled study on a group of 37 children with Sydenham chorea. up to 5% of patients allergic to penicillin may also be allergic to cephalosporins. but at the cost of higher recurrence rates.72.000 units intramuscular (#27 kg) or Dovepress A large multi-center study in the United States and United Kingdom in 1955 compared the efficacy of aspirin. the hormonal treatments caused more rapid resolution of some symptoms. or worsen existing valve damage.69 It is important to note that these strains are based only on data from the United States. The 26 chosen strains were those associated with pharyngitis. cortisone.66. the exact action of effect is unclear. Note.75 or heparin. Secondary antibiotic prophylaxis should be given to individuals most at risk for GABHS pharyngeal infections.000 units intramuscular (. This was seen in an early M-protein vaccine trial in the 1960s where all patients receiving the vaccine developed antistreptococcal antibodies. with over 150 M-types identified. compared to 5 of 447 controls.71 Acute treatment Salicylate therapy for the symptoms of ARF was first attempted successfully by Maclagan in 1876. Patients who have recurrences of ARF are at risk to develop carditis. Inc. aspirin has remained the first line treatment for uncomplicated ARF. Studies in areas highly endemic for ARF have found that BPG dosed every 3 weeks provides better prevention of recurrent ARF. and ARF. These include children.22 Anti-inflammatory medications are given until the inflammatory markers normalize. with conserved.27 kg) Drug-dependent Penicillin V Sulfadiazine Macrolidea Notes: aIn penicillin-allergic patients.21. the decision about which M-types to include was based on the United States Centers for Disease Control’s Active Bacterial Core Surveillance of the Emerging Infections Program Network. Source: American Heart Association. which can help distinguish ARF from other arthritides which do not resolve as quickly.80. which will be discussed more later.62 corticosteroid treatment for chorea is a logical choice. a variety of treatments have also been attempted for ARF. so-called “rheumatogenic” strains. and adrenocorticotropic hormone for the acute treatment of the symptoms of ARF. Antibiotic choices are similar to those for GABHS pharyngitis. and hypervariable regions. invasive disease.74 administration of ascorbic acid and orange juice. treated 22 with prednisone.27 kg) Every 4 weeks (3 weeks in high-risk areas/populations) 250 mg by mouth twice daily 0. Antibiotic Dose Benzathine penicillin G 600. and so this population is best treated with secondary antibiotic ­prophylaxis after their initial attack (Table 3). For the 26-valent GABHS vaccine.68 Since ARF is thought to be due to an autoimmune response to the M-protein and molecular mimicry of the heart valve tissue. Given the inflammatory changes seen on pathologic specimens. but seems to be related to the anti-inflammatory properties.dovepress.

­Overall. Table  6  shows the percentages of patients with the Major and Minor criteria for each WHO region and for all reported studies combined. and healthcare workers. 85 utilized population-based screening.049). The reported incidence of ARF is decreasing in all WHO Regions except for the Americas where it appears to be increasing slightly and the Western Dovepress 73 .Dovepress Epidemiology of rheumatic fever Table 4 Reported incidence of acute rheumatic fever (ARF) (per 100. Those with RHD should be treated until 40 years of age or 10 years after their last attack. carditis occurred in 60% of cases. The Americas also had more cases of chorea than the Eastern Mediterranean (P = 0.002. surgical series. The most important component of these guidelines is the need to assess each patient’s clinical situation to determine if they have continued high-risk exposure to GABHS which could warrant lifelong prophylaxis.8 1. and the only significant difference between regions was a higher male predominance in Southeast Asia compared to the Western Pacific (P = 0. where it appears to be steadily increasing. whichever is longer.4 Fijians Indians Papago tribe 78 21.6 → 2. Figures 8 and 9 are graphs of the trend of ARF incidence and RHD prevalence for each WHO Region. or autopsy series.5–55 12–14 120 27 112 15. national health registries.019 and 0. respectively).7 4. The American Heart Association guidelines state that individuals who have had ARF without carditis should be treated until the age of 21 years or 5 years after their last attack. where it appears to be decreasing. as any of the four cardiac valves can be affected by ARF. and ESR elevation was less in Southeast Asia than in the Eastern Mediterranean and Western Pacific (P = 0.dovepress. There were more cases of erythema marginatum in the Americas than in Southeast Asia (P  =  0.1 10–30 1.9 1. prospective disease surveillance. It is also recommended to continue prophylaxis after heart valve Table 5 Reported prevalence of rheumatic heart disease (RHD) (per 1000 persons) from 1935 through 1970 Years Country RHD (/1000) 1935–1964 1949–1951 1958–1961 1961 1964–1965 1966 1970 1970 United States (Minnesota)86 United States (Colorado)88 Japan98 USSR99 Pakistan (Karachi)100 India (Chandigarh)101 Taiwan (Taipei)102 Uruguay103 20.6 4. The literature review revealed data on the incidence and/or prevalence of ARF and RHD in 100 countries around the world. Europe and the Eastern Mediterranean (P = 0. Fever and an elevated ESR were reported less often in Africa than any of the other regions. respectively).013.041. Tables 4 and 5 show the reported incidence of ARF and prevalence of RHD for the era before 1970.019.4 African Americans Puerto Ricans 47 Whites 23 African Americans Whites 44. Figures 4 through 7 present the incidence of ARF and prevalence of RHD during the 1970 to 1990 and 1991 to present eras.65.005 and 0.000 persons) from 1930 through 1970 Years Country 1930–1964 1935–1949 Sweden United States (Minnesota)86 England (Bristol/Sheffield)87 United States (Colorado)88 Costa Rica89 Peru90 Sri Lanka91 United States (Maryland)92 United States (Utah)93 United States (New York)94 United States (New York)94 United States (New York)94 United States (Tennessee)95 United States (Tennessee)95 Denmark85 Fiji96 Fiji96 United States (Arizona)97 1948–1953 1949–1961 1950 1952 1952–1957 1960–1964 1960–1964 1963–1965 1963–1965 1963–1965 1963–1969 1963–1969 1966 1965–1966 1965–1966 1970 Subgroup ARF (/100.003.011 and 0.015 and 0. 0. data from specialty referral clinics.025). teachers. all studies were included. or studies from which the data collection methods could not be determined.8 1. respectively).66 Results Of the 164 articles reviewed for ARF incidence and RHD prevalence data.7–6.000) 25 → 1. whichever is longer. and in the Western Pacific than in both the Eastern Mediterranean and Southeast Asia (P = 0. college students).6 → 12 6.3 35–65 85 25. Arthritis also occurred in 60% of all cases and Southeast Asia had significantly fewer cases than the Americas. The reported prevalence of RHD is increasing in all regions except for Europe.015). respectively). Seventy-nine studies were retrospective reviews of hospital admissions or discharges for ARF or RHD. In order to maximize the available data. parents. Elevated submit your manuscript | www. There was a slight male predominance in all ARF cases.5 13 140 92 (military recruits.4 1 Clinical Epidemiology 2011:3 replacement surgery. but the Americas had significantly fewer cases than the Western Pacific or Southeast Asia (P = 0.

133 (10) Qatar.013. and 0. . Eastern Mediterranean. 120.120 (7) Kuwait.Seckeler and Hoke Dovepress ARF (/100.182 (8) New Caledonia.178 (5) Jordan.dovepress. and both combined (Figure 10c).199 74 submit your manuscript | www. and in the Americas and Eastern Mediterranean than in Southeast Asia (P  =  0.112 (9) Northern Mariana Islands. arthralgia. respectively). and Southeast Asia (P = 0.025. showing M-types from developing nations (Figure 10a).40.049).136 (12) Trinidad.179 (6) Kosrae.86.152 (24)Utah.123-125 (8) New Caledonia.133 (10) Samoa.112 (3) French Antilles.026 and 0.104-156 (1) Barbados.112 (5) Federated States of Micronesia.147 (20) Navajo Reservation.005. Africa had fewer recurrences than Southeast Asia (P = 0. There was no difference in subcutaneous nodules. Western Pacific.93 (25) Virginia. 111. developed nations (Figure 10b). and Western Pacific than in Africa (P = 0.97 (15) California.175 (4) Israel.0. 151 (23) Tennessee. For ARF (/100. 0. Federated States of Dovepress Clinical Epidemiology 2011:3 . or first-degree heart block between all 6 regions. The reported M-types are presented in Figure 10.113 (4) French Polynesia. 156-200 (1) American Samoa.185 (9) Northern Mariana Islands.036.159.86 (19) Mississippi. 139. respectively).112. 115.114 (6) Israel.190 (11) West Virginia.181 (7) Lebanon.155 (27) Wyoming. and 0.112 (11) Tonga.97 ASO titer was more common in the Americas. respectively).142 (16) Florida. There were not enough data available to compare differences in Major and Minor criteria between the two eras to evaluate for changes in presenting Jones criteria over time.000 persons) <5 5–20 20–40 40–100 >100 Figure 4 Map showing reported worldwide incidence of ARF from 1970 through 1990.022.141. Regional ARF recurrence rates ranged from 8% to 34%.143 (17) Hawaii.153 (26) West Virginia.001.140 (14) Arizona.001.105 (2) Fiji.144-146 (18) Minnesota.169-171 (3) Grenada.150 (22) Rhode Island. Europe.148 (21) Ohio. with Europe having significantly fewer recurrences than the Americas.004.000 persons) <5 5–20 20–40 40–100 >100 Figure 5 Map showing reported worldwide incidence of ARF from 1991 through present.149.97. 108.137 (13) Alabama.192 (2) Fiji. Eastern Mediterranean. 0.

only 50% of patients diagnosed with ARF had laboratory evidence of a recent streptococcal infection demonstrated by an elevated or rising ASO titer.136. where public health resources are limited. As might be expected.112.112 (9) Tonga. in Figure  10 the 26 M-types present in the GABHS vaccine currently being tested are noted by an asterisk.228 (2) Samoa.99.177.86 comparison.191. In Dovepress 75 .168.000 persons) <1 1–2 2–4 4–10 >10 Figure 6 Map showing reported worldwide prevalence of RHD from 1970 through 1990. RHD (/1.118.112 (5) French Polynesia.102-104. especially those presenting data from specialty referral clinics or hospital admissions.112.169. practice patterns for ARF diagnosis vary across countries.21. However. All patients diagnosed with ARF were treated accordingly.202 (7) Puerto Rico. which is a disappointment from a public health standpoint.192 (3) Tonga. The inherent limitations to the methods of many reviewed studies.3 Clinical Epidemiology 2011:3 submit your manuscript | www.202 (4) Fiji.Dovepress Epidemiology of rheumatic fever RHD (/1.21 (3) El Salvador.189. do not allow calculation of exact incidence rates.103 (8) Samoa.132.169.201-216 (1) Barbados.21. these data make clear that ARF and RHD still exist in significant numbers around the world.197.86.112 (6) Jamaica.104 (2) Cook Islands. persons) <1 1–2 2–4 4–10 >10 Figure 7 Map showing reported worldwide prevalence of RHD from 1991 through present.217-240 (1) Fiji.14.111.241 Discussion This is the most comprehensive review of the incidence and prevalence of ARF and RHD in the English literature to date.2-6.136 (10) Minnesota.160.dovepress.192.

These countries have small. E) Western Pacific. Similar practice patterns can be noted in the other poorer WHO regions – Western Pacific and Southeast Asia. which has contributed to an increased prevalence of RHD.000 1986 1984 1982 1980 0 Year E 1988 20 1978 2008 2006 2004 2002 2000 1998 1996 1994 1992 1990 1988 1986 1984 1982 1980 1978 1976 1974 1972 0 40 1976 50 60 1974 100 80 1972 150 100 1970 D Incidence per 100. C) Africa. A) The Americas.000 persons for each WHO region.000 Year 200 1970 C Incidence per 100. The reported incidence is only now approaching an average 100/100. which is likely what the true incidence has been. Given that the incidence of ARF has been decreasing in most regions.000 people.dovepress. Because of the endemic nature of ARF in these regions and the marked impact of progression to chronic RHD. This trend has been attributed to improved living conditions. RHD is also more rigorously sought out.2–6 Recognition of subclinical carditis will identify those children who would benefit from secondary antibiotic prophylaxis and hopefully prevent the progression to clinically significant RHD. Points represent reported incidence from the literature. The apparent increase in incidence in the Western Pacific is more likely improved recognition and reporting of ARF in this region. their increased likelihood Clinical Epidemiology 2011:3 . Nevertheless. One possibility for the high incidence of ARF in the Western Pacific region is that many of the countries are small island nations.000 Year 1986 1984 1982 1980 1978 1976 1974 1972 400 350 300 250 200 150 100 50 0 1970 2008 2006 2004 2002 2000 1998 1996 1994 1992 1990 1988 1986 1984 1982 1980 1978 1976 1974 1972 Incidence per 100. and so even a small outbreak of ARF can be calculated as a high incidence level. The decrease in ARF incidence is consistent with prior studies that have shown the incidence to be decreasing since the early 20th century. relatively 76 submit your manuscript | www.133.161 The prevalence of RHD appears to be increasing worldwide.000 B 700 600 500 400 300 200 100 0 1970 A Incidence per 100.Dovepress Year 2008 2006 2004 2002 2000 1998 1996 1994 1990 1992 1992 1994 1996 1998 2000 2002 2004 2006 2008 1992 1994 1996 1998 2000 2002 2004 2006 2008 1990 1988 50 1990 1988 1986 1984 1982 1980 0 1978 2008 2006 2004 2002 2000 1998 1996 1994 1992 1990 1988 1986 1984 1982 1980 1978 1976 1974 1972 0 100 1976 50 150 1974 100 200 1972 150 250 1970 F 200 Incidence per 100. it is not likely due to increases in the disease. ­Population-wide echocardiographic screenings may be subject to length time bias or pseudodisease. The upward trend in our calculated incidence of ARF in the Americas is likely due to the high incidence reported from Mexico in 1995.000 Year 250 1970 Incidence per 100. given relatively small denominators. it is reasonable to be aggressive with ARF diagnosis and treatment. and F) Southeast Dovepress isolated populations. Major advances in medical and surgical treatments for RHD have led to increased survival. the use of antibiotics for GABHS pharyngitis and possibly shifting GABHS serotypes. B) Europe. and the children diagnosed are likely to be among the majority of ARF patients in whom carditis resolves within a year of initial attack.000 Seckeler and Hoke Year Figure 8 Trends of acute rheumatic fever incidence per 100. which is easily seen as an outlier in the maps in Figures  4 and 6. D) Eastern Mediterranean. and newer studies relying on echocardiography to enhance the diagnosis of RHD have shown that subclinical carditis exists at rates up to 10 times higher than that diagnosed by examination alone.

9% 75.7% 50.8% 8.0% 7.5% 40.7% 2. ↑ PR.7% 28.7% 54.8% 5.7% 48.9% 48. ESR. increased erythrocyte sedimentation rate.9% 63.6% 24.243 These are similar to Gordis’ findings from the 1970s in Baltimore.000 Year 35 30 25 20 15 10 5 0 1970 Prevalence per 1. Abbreviations: EM.5% 4.6% 33.7% 20.4% 3. c) Africa.3% 84.2008 2006 2004 2002 2000 1998 1996 1994 1992 1992 1994 1996 1998 2000 2002 2004 2006 2008 1992 1994 1996 1998 2000 2002 2004 2006 2008 1990 50 40 30 20 10 Year 1990 1988 1986 1984 1982 1980 1978 1976 1974 0 1972 2008 2006 2004 2002 2000 1998 1996 1994 1992 1990 1988 1986 1984 1982 1980 1978 1976 1974 1972 60 1970 F Prevalence per 1. especially in endemic areas.7% 68.5% 34.243 A recent meta-analysis of the treatment of GABHS pharyngitis to prevent ARF concluded that there would be an approximately 60% reduction in cases of ARF if pharyngitis was appropriately treated.3% 46.8% 1.4% 22.dovepress. ASO.0% 4.9% 35.9% 24.000 Dovepress Year Figure 9 Trends of rheumatic heart disease prevalence per 1000 persons for each WHO region.242.1% 55. or even ARF without a clinically apparent preceding sore throat as missed opportunities to prevent ARF. and worsening of prior valvar lesions. prolonged PR interval on ECG. makes it appropriate that these children receive secondary antibiotic prophylaxis.3% 60. of recurrent ARF.3% 64.9% 11.4% 71.4% 74. b) Europe.5% 1.7% 22.4% 72. a) The Americas.2% 81. elevated antistreptolysin O titer.7% 35.4% 53.1% 54. Points represent reported prevalence from the literature.9% 43.3% 60.9% 52.9% 68. there is little excuse for hundreds of thousands of new cases of ARF annually.9% 90.8% 8.9% 67.3% Note: Proportions are restricted to acute rheumatic fever patients.1% 45. d) Eastern Mediterranean.3% 48.5% 7. poor compliance with antimicrobial regimens.3% 8.3% 12.4% 12.8% 5.5% 63. Clinical Epidemiology 2011:3 submit your manuscript | www.8% 15.6% 40.3% 65.5% 66. e) Western Pacific.0% 3.4% 78.0% 71.000 Epidemiology of rheumatic fever 1970 A Prevalence per 1.8% 62.0% 59. Authors cite varying reasons such as patients not seeking care for pharyngitis.3% 26.5% 52.9% 81.5% 79.9% 21.000 Year 1970 1972 1974 1976 1978 1980 1982 1984 1986 1988 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 C Prevalence per 1.5% 54.4% Dovepress 77 . erythema marginatum.1% 91.3% 22.7% 15. and f) Southeast Asia.9% 17.242 Implementing systematic sur- Table 6 Percentage of major and minor criteria by WHO region and for all reported studies WHO region Males Recurrences Major criteria Minor criteria Carditis Arthritis EM Chorea Nodules Arthralgia Fever ↑ PR ESR ASO The Americas Europe Africa Eastern Mediterranean Western Pacific Southeast Asia All 54.7% 86.2% 57.0% 63. Given the relative ease and low cost of GABHS pharyngitis treatment to prevent ARF occurrence.000 Year 1988 1986 1984 1982 1980 1978 1976 1974 1972 2008 2006 2004 2002 2000 1998 1996 1994 1992 1990 1988 1986 1984 1982 1980 1978 1976 1974 1972 40 35 30 25 20 15 10 5 0 1970 B 40 35 30 25 20 15 10 5 0 Prevalence per 1.9% 1.3% 11.0% 59.000 1988 1986 1984 1982 1970 0 Year E 1990 5 1980 0 10 1978 5 15 1976 10 20 1974 15 1972 D 20 Prevalence per 1.9% 27.0% 0.8% 23.

244 In highly endemic areas. veillance and treatment of GABHS pharyngitis.2 2 3 4 5 6 8 9 10 11 12 13 14 15 17 18 19 22 24 25 26 28 29 33 41 42 43 44 46 48 49 52 53 54 55 56 57 58 59 60 62 63 65/69 66 67 68 71 73 74 75 76 77 78 81 82 83 85 86 87 89 92 93 94 95 98 100 101 102 103 104 105 106 108 109 110 112 114 116 118 120 122 123 NT C Number of countries reporting M-type M-type Figure 10 Number of reported occurrences of each streptococcal M-type in a) developing nations. given the increased occurrence of ARF among families and monozygotic twins. personal communication).Dovepress 12 * 10 8 * * * 6 * * * * * * * * * 4 * * 2 * * 0 * * * * * * * * * 1 1.2 2 3 4 5 6 8 9 10 11 12 13 14 15 17 18 19 22 24 25 26 28 29 33 41 42 43 44 46 48 49 52 53 54 55 56 57 58 59 60 62 63 65/69 66 67 68 71 73 74 75 76 77 78 81 82 83 85 86 87 89 92 93 94 95 98 100 101 102 103 104 105 106 108 109 110 112 114 116 118 120 122 123 NT B Number of countries reporting M-type 18 * 16 14 * 12 * 10 8 * 6 * * * * * * * * * 0 * * 4 2 * * * * * * * * * * * 1 1. some providers choose to empirically treat patients in the 5. it is hard Clinical Epidemiology 2011:3 .D. is crucial to the control and prevention of 15-year age range with fever and complaints of sore throat.245 The variability in reported HLA alleles associated with ARF and RHD could be due to genetic differences in the populations studied or differences in local streptococcal strains. Note: *denotes M-types contained in 26-valent GABHS vaccine. Given the current state of the literature.27–45. but there are still many other HLA alleles that are identified in only single studies.2 2 3 4 5 6 8 9 10 11 12 13 14 15 17 18 19 22 24 25 26 28 29 33 41 42 43 44 46 48 49 52 53 54 55 56 57 58 59 60 62 63 65/69 66 67 68 71 73 74 75 76 77 78 81 82 83 85 86 87 89 92 93 94 95 98 100 101 102 103 104 105 106 108 109 110 112 114 116 118 120 122 123 NT A Number of countries reporting Seckeler and Hoke 8 7 * 6 5 * 4 * * * 2 0 * * * 3 1 * * * * * * ** * * ** * * * * * * 1 1. With the low risk of side effects or induction of antibiotic resistance with penicillin therapy compared with the significant risk associated with ARF. even without any laboratory evidence of GABHS infection (M.dovepress. nontypeable. Abbreviation: NT. this strategy may be justified.28..S. b) developed nations. particularly through school-based programs. 78 submit your manuscript | www. and c) both combined.245 The HLA-D8/17 and HLADR7 types are the most represented in the literature among patients with ARF and Dovepress The likelihood of genetic susceptibility to ARF is high.

Archard LH. Prevalence of rheumatic heart disease in school children of urban Lahore. Circulation. 1992. Naito S. 27. 2010. Carapetis JR. Lancet. 1992 Update. Jones criteria (revised) for guidance in the diagnosis of rheumatic fever. Paine A. in the end. Am Heart J. As discussed previously. Wilson W. 28. but they are all currently in the experimental stage. The logic for extending the use of echocardiography beyond childhood to detect subclinical rheumatic heart disease. 21. J Clin Invest. Despite our major advances in medical technology and understanding.16: 555–570. Panwar RB. Jones criteria (revised) for guidance in the diagnosis of rheumatic fever. Douglas R. Pan Z. Poynton FJ. and 81. 1889.29:619–623. Evaluation of a screening protocol using auscultation and portable echocardiography to detect asymptomatic rheumatic heart disease in Tongan schoolchildren. ­Endocarditis and Kawasaki Disease of the Council on Cardiovascular Disease in the Young of the American Heart Association. HLA and rheumatic heart disease in Japanese. 357:470–476. Weber M. Am J Cardiol. Scand J Immunol. Subclinical valvulitis in children with acute rheumatic fever. the availability of a GABHS vaccine would be the best form of ARF prevention. Guidelines for the diagnosis of rheumatic fever. increase an individual’s susceptibility to ARF and RHD. 2002. Marijon E. Tani LY. Zhang H. Heart. Clin Microbiol Rev.9:186–206. Ann Pediatr Card. Circulation. 1944. Beattie JM. Brown A. in combination. not vaccinating against prevalent M-types. Bhaya M. 1975. 2007. 7. Lancet. communicability and heredity in their relation to the observed familial incidence of the disease. especially since not all patients report upper respiratory infection symptoms or sore throat before their initial ARF occurrence.70:213–218. et  al.Dovepress to make generalizations about a single “rheumatic” HLA allele. Cirak MY. Ou P. 17.106:2521–2523. Ji Y. While a greater understanding of the detailed mechanisms of disease onset will advance scientific knowledge. 25. Geneva: WHO. Olgunturk R. 923). Circulation. et al. 3. Rheumatic fever and rheumatic heart disease: genetics and pathogenesis. 2009. Pediatr Cardiol. Geneva. Schweitzer MD.66: 199–207. World Health Organization. Carapetis JR. Berrios NM. 2007. 8. The role of viral agents in ­aetiopathogenesis of acute rheumatic fever.27:448–453. [Epub Apr 19]. it may not matter if one person is more susceptible to developing chorea when exposed to streptococcal M-type 19 or another to developing carditis when exposed to streptococcal M-type 49. 105:1809–1814. Abid R.5:411–417. both will develop some form of ARF. Diagnosis of rheumatic fever. especially in developing nations where ARF and RHD are endemic. Panwar S. 2005.268:2069–2073. 18. as shown in Figure 10. Cardiol Young.dovepress. Viruses and rheumatic fever. Celermajer DS. Minich L. (WHO Technical Report Series No. Preventing or providing early treatment for streptococcal infections will be the most important step to worldwide ARF eradication. High prevalence of rheumatic heart disease detected by echocardiography in school ­children. 156:861–869. 12. 1907. 29 Oct – 1 Nov 2001. Guilherme L. 13. and the common denominator is exposure to GABHS. 15. Special Writing Group of the Committee on Rheumatic Fever. 2010. WHO programme for the prevention of rheumatic fever/rheumatic heart disease in 16 developing countries: report from Phase I (1986–90). Hassall IB. Prevalence of rheumatic heart disease in children and young adults in Nicaragua.69:204A–208A. However. Rose JD. 1983. Veasy LG. Prevalence of rheumatic heart disease detected by echocardiographic screening.186:581–586.106(5 Pt 1):1164–1167. 2005.13:470–511. 133:821–827. An Australian guideline for rheumatic fever and rheumatic heart disease: an abridged outline. Ferrieri P for the Jones Criteria Working Group. JAMA. 23. Li Y. 2007. This is an area that needs continued research efforts to help target ARF prevention strategies to higherrisk populations. Echocardiography.2:319–322. Beg A. Nat Clin Pract Cardiovasc Med. Med J Aust. 58. 26. 16. Proceedings of the Jones Criteria Workshop. Environment. Caughey DE. 1977. 10. Echocardiography in acute rheumatic fever. Sadiq M. JAMA. It is hoped that presenting the continued worldwide problem of ARF and RHD will help promote further study into strategies to reduce the burden of this disease.95:353–357. J Exp Med. WHO Cardiovascular Diseases Unit and principal investigators. Lancet Infect Dis. et al. and there are likely multiple HLA alleles that.5: 685–694. Br Heart J. Ramasawmy R. may be missing the opportunity to prevent many cases of ARF.33:536–538. 2008. Sadiq Dovepress 79 . Harveian lectures on the various manifestations of the rheumatic state as exemplified in childhood and early life. submit your manuscript | www. Carapetis JR. Heart. Steer AC.126:481–484. 2010. WHO Expert Consultation on Rheumatic Fever and Rheumatic Heart Disease. 2. the M-types present in the 26-valent GABHS vaccine being developed do not represent many of the M-types found in the developing world. 5. J Rheumatol. Recognition of rheumatic heart disease. The etiology of rheumatic fever. Jones Criteria. Clin Rheumatol.68 Rheumatic fever remains a serious public health problem throughout the world. References 1. Kalil J. 2000. Rheumatic fever and rheumatic heart disease: report of a WHO Expert Consultation. Fleming PR. 2004. Wilson MG. Kitajima K. A contribution to the bacteriology of rheumatic fever. Arakawa K. Since we do not know all the possible “rheumatogenic” M-types. Paar JA. Ramakrishnan S. et al. Jones TD. Cheadle WB. Clinical Epidemiology 2011:3 Epidemiology of rheumatic fever 4. 1935. 6. 2009. Bull World Health Organ.19:30–33. N Engl J Med. 1937. Edwards KN. HL-A antigens in europeans and maoris with rheumatic fever and rheumatic heart disease. 2008. we have not eradicated this disease.2:61–64. The global ­burden of group A streptococcal diseases. The vaccines that target the conserved region of the M-protein are likely to provide better protection. Beniwal R.91: 87–88. 39:1045–1050. Canad M Ass J. 9. 2009. et al. 11. Wilson NJ. Pathogenesis of group A streptococcal infections. Okur I. Islam K.32:664–668. 1984. 1992. 24. 14. Hardy M. Herpes simplex virus type 1  infection in rheumatic valvar disease. 19. 1900. Mulholland EK. Rheumatic fever as a familial disease. such as 49. 20. Fakakovikaetau T. 1965. 22. 29. Disclosure The authors report no conflicts of interest. Cunningham MW.

Maharaj B. By Patrick J. Pelouch R. 45. 2007. 47. Red Book: 2009 Report of the Committee on Infectious Diseases. 37. 64.184:507–510. 2002. 56. J Neurol. Kalil J. 63. Singer HS. B. IL: American Academy of Pediatrics.22:49–52. Sydenham Chorea: magnetic resonance imaging reveals permanent basal ganglia injury. Long SS. HLA class II associations with rheumatic heart disease among clinically homogeneous patients in children in Latvia. Malamud N. 1945. medical illustrator)[see page for license]. Curtis N. Kaplan MH. Lee O. Postol E. the Interdisciplinary Council on Functional Genomics and Translational Biology. Snitcowsky R.9:25–34. Yakut C. Zabriskie JB. Beall B. 1997.jpg. Taneja V. 1993. clinical and microbiological profile of infective endocarditis in a tertiary hospital in the South-East Anatolia Region. 2007. Stanevicha V. Infective endocarditis in the Czech Republic: eight years of experience at one of the country’s largest medical centers. 2009. Ozenirler S. Flores-Domínguez C. Ozer O. 2010. Moller JH. Med J Aust. Cardiovasc Pathol. 2007. Farahati J. Circulation. Cunningham MW. Lederman HM. ­Association of human leukocyte class II antigens with rheumatic fever or rheumatic heart disease in a Brazilian population. Curr Opin Mol Ther. Davutogˇlu V. 55. Binstadt BA.83:1995–1998. et  al. DR. 2009. Frengley JD. Harel L.83:1710–1716. Heart apical 2C anatomy. Carin M. J Clin Immunol. Warnnissorn M. Eaton CB. Zavadska D. Emery ES. psychiatric and magnetic resonance findings in patients with Sydenham chorea. Eglite J. Vieco PT. Circulation. Jergas M. Heart. 49. Human leukocyte antigen (HLA) class I and II alleles in Turkish patients with rheumatic heart disease. Aksoy M.30:17–23. Guilherme L. Studies on the pathogenesis of rheumatic fever: I. Aguilar-García J. Stroop SD. El-Hagrassy N. 34. 2009: 616–628. Neurology. Accessed October 28. Circulation. Hilário MO. Arthritis Res Ther. 2005. Kiss MH.93:1510–1519. Olive C. Heye N. 2010. Pazdernik M. 60. HLA class I and class II HLA DRB profiles in Egyptian children with rheumatic valvular disease.45: 456–462. 2007.119: 1541–1551. Williams RC Jr. Chuangsuwanich T. Pudifin DJ. Clinical. Neuroradiology. Donadio Dovepress Dovepress 51. and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young. Immunogenicity of a 26-valent group A streptococcal vaccine. MRI and SPECT findings in the early stage of the disease. In: Pickering LK. via Wikimedia Commons. Islamoglu Y. ­Experimental production of autoantibodies to heart.60:379–381.76:259–261.Seckeler and Hoke 30. 1989. HLA-DR/DQ antigens and reactivity to B cell alloantigen D8/17 in Indian patients with rheumatic heart disease. 2009. HLA-A. Kimberlin DW. Terreri MT. Hammond MG. HLA antigens in Turkish race with rheumatic heart disease. Loiselle CR. Currie BJ. Garvey MA. El-Chennawi F.24:459–473. Arthritis Res Ther.dovepress. and DQ antigens in Indian patients with severe chronic rheumatic heart disease. Lynch. Turk Kardiyol Dern Ars. Kaplan MH. 48. Colquhoun SM. Circulation. 2006.7:1517–1524. Leksrisakul P. Baddour LM. et al. Scand J Rheumatol. Sydenham chorea: clinical. 2003. 68. 2003. Zavadska D. 1997. Khedun SM. 43. Freschi de Barros S. A vaccine against S. 40. ­Gardovska D. Cavelti PA. 52. Hernández-Pacheco G. 32.240:121–123. Mehra NK. Proc Soc Exp Biol Med. Current concepts of the relation of autoimmunity to rheumatic fever.80:335–340. Lancet. EEG. Heuser JS. laboratory. B-cell antigen D8/17 is a marker of rheumatic fever susceptibility in Aboriginal Australians and can be tested in remote settings. 1991. 2003. and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. 1989. Pediatr ­Cardiol. Nkomo VT. 53. Zaki A. Dalalio MM. 31. Guilherme L. Infect Immun. J Heart Valve Dis. 1947. Presence of a non-HLA B cell antigen in rheumatic fever patients and their families as defined by a monoclonal antibody. Pereira FC. postcardiotomyand postinfarction syndromes and cardiomyopathies. Association of HLA-DR7 with rheumatic fever in the Brazilian population. 39. Arch Pathol (Chic). Gündogdu F. 61. MHC class II alleles in Mexican patients with rheumatic heart disease. Walls MA. Khanna AK. 49:316–321. Fawzy H. Arch Pathol (Chic). 2007. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever. ­Shantere R. Maharaj B. Rheumatic fever and rheumatic heart disease: cellular mechanisms leading autoimmune reactivity and disease. J Clin Invest. 28th ed. Turgay M. Colony HS. Carapetis JR. et  al. Gardovska D. Leary WP. Appadoo B. Cardiac operations for North ­American children with rheumatic diseases: 1985–2005. Amir J. 66. Moliterno RA. Baltimore RS. 54.18:395–400.91:3–4. Visvanathan K. Hötzinger H.136:154–161. Thongcharoen P.279: 706–710. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Am J Cardiol. Pirim I. Rheumatic heart disease and its control in the Pacific.48: 531–533. 2010. American Academy of Pediatrics.9:R58. 62. Sochnevs A. Grus FH. Kalil J. Zappitelli MC. Ozdemir M.92:49–54. 80 submit your manuscript | www. Hu MC. 2009. Hammond MG. Joseph N. Eglite J.16:293–299.61:293–298. Shantere R. Faustino PC. epidemiological. Reddy commons/f/f9/Heart_apical_2C_anatomy. Kado JH. 1962. Straussberg R. Zaki Mel-S. ­Cardiac lesions produced in rats by means of autoantibodies to heart and ­connective tissues. Stingl C. et al. HLA-A. DR. Clinical Epidemiology 2011:3 . J Heart Valve Dis. Sönmez G. http://upload.16:104–110. Heart. 58. van der Byl K.70:2171–2177. Autoantibodies in rheumatic fever. J Rheumatol. HLA class II DR and DQ genotypes and haplotypes associated with rheumatic fever among a clinically homogeneous patient population of Latvian children.9:914–920. Elk Grove Village. 46. Harrington Z.wikimedia.44:1–12. Baker CJ. Pöhlau D. Kirvan CA. Kaplan EL. pyogenes: design and experimental immune response.27:1518–1520. Int J Cardiol. Sucu M. 1993. Zeharia A. 2003. and laboratory investigation. Weidebach W. 1987. Clin Genet. Swedo SE. da Rocha AJ. B. 35. et al. Cavelti PA. Samanthai N. Lynch.87:1974–1978. 2003. Carapetis JR. medical illustrator (Patrick J. Dale JB. Olmez U. Kodman Y. Epidemiological. Reddish MA. Stanevicha V. Guilherme L. 1969. Methods.38: 107–111. 2000. 42. Sydenham’s chorea: a clinicopathologic study. Expert Rev Cardiovasc Ther.5:R340–R346. Jpn Heart J. et al. Ozkan M. 59. and DQ antigens in black patients with severe chronic rheumatic heart disease. Presence of the d8/17 B-cell marker in children with rheumatic fever in Israel. Cheunsuchon P. 65. Cavelti PA. Tsuneto LT. Pediatr Cardiol.44:13–27. 2002. Anti-basal ganglia antibody abnormalities in Sydenham chorea. 1956. Przuntek H. Neurology. Nat Med. 50. 1993. Steer AC. Autoimmunity to the heart in cardiac disease. 36. 38. Endocarditis. Meyeserian M. 2010.38:663–668. An immunological cross-reaction between group-A streptococcal cells and human heart tissue. 57. Gerber MA. 2010.6:672–676. 69.31:650–656. Progress in M-protein-based subunit vaccines to prevent rheumatic fever and rheumatic heart disease. 1947. Epidemiology and prevention of valvular heart diseases and infective endocarditis in Africa. 41. Circulation. Studies on the pathogenesis of rheumatic fever: II. Sochnevs A. Buskirk DR. Skinner NA. J Neuroimmunol. Group A streptococcal infections. Senocak M. 67.31:66–73. et al. Pathogenesis of acute rheumatic fever and rheumatic heart disease: evasive after half a century of clinical. skeletal muscle and connective tissue. Surgical pathology and etiology of 278 surgically removed mitral valves with pure regurgitation in ­Thailand. Association of HLA class I and class II antigens with rheumatic fever in a Turkish population. editors. 44. Visentainer JE. 33.

J Clin Invest. Albert DA. Br Heart J.121:569–572. 1976–1981. The treatment of acute rheumatism by salicin.T. Treatment of acute rheumatic fever in children a co-operative clinical trial of A. Surveillance of streptococcal infections in children in a south Indian community – a pilot survey. Arguedas A.C. Pac Health Dialog. Sievers J. Veasy LG.H. Neutze JM. Report of a WHO Study Group. Wilson C. Benjamin V. ­Georgakopoulou T. Tauber T. Prevention of rheumatic fever in Costa Rica.1:13–18. submit your manuscript | www. Padeh S. Rheumatic fever and rheumatic heart disease in Japan.34: 264–269. Sarmiento L.59:599–603. Naproxen as an alternative to aspirin for the treatment of arthritis of rheumatic fever: a randomized trial. Acute rheumatic fever – no epidemic in Ontario. del Campo E. Chalons S. Bull World Health Organ. Negus RM. 80. Can Med Assoc J. 1959. Incidence of acute rheumatic fever. N Engl J Med.28:228–234. 1968. 1966. The treatment of rheumatic carditis by roentgen irradiation of the heart.134:703–712. Leff S. Kostaridou S.34: 143–149. 113. 1963–1969. Ferguson CA. The use of naproxen in the treatment of children with rheumatic fever. 2010. Taran LM. et al for the Pediatric Rheumatlogy Study Group of Israel. Goldman R. 1982. Lilienfeld A. 1988.dovepress. Prevention and control of rheumatic fever and rheumatic heart disease: the Cuban experience (1986–1996–2002). Alto W. 764):5–58.33:833–836. Luque C. Corbett JJ. N Z Med J. Rheumatic fever and rheumatic heart disease. Mohs E. 99. The incidence of rheumatic fever in ­metropolitan Nashville.101(847 Pt 2):404–406.90:809–812. J Pediatr. Studies in the epidemiology and preventability of rheumatic fever – I. 72.S. Berríos X. 77. Levy RL.127: 497–498. Appl Microbiol. Silva CA. Wu MH. 1935–1978.137:269–271. Kassem E. Indian J Med Res. 79. Hutten-Czapski P. Torres JM. Lopez R. Hashmi JA. Brownell KD. Somekh E. Wiedmeier SE. Br Med J. Federspiel CF. Berry JN. Am J Epidemiol. Araya M. 108. 15:33–39.57:753–757. 1955. et  al. The Barbados experience. II. NZ Med J. 1970. WHO Chron.107:342–343.50:1241–1245.347:644–648. Kao H. World Health Organization. Acta Paediatr.40:94–96. ­I ncidence in a borough of New York City. Anagnostopoulos G. 1977. Pillman NL. 1950–2003. Phibbs B. 109. A joint report by the Rheumatic Fever Working Party of the Medical Research Council of Great Britain and the Subcommittee of Principal Investigators of the American Council on Rheumatic Fever and Congenital Heart Disease.34:247–249. 1987. Cherian G. 1982. Arguedas A. 1949. 1936. 86. Lancet. Nordet P. Morales A. Secondary and apparent primary antibody responses after group A streptococcal vaccination of 21 children. Wolach B. Weidman WH. 87. Watson WB. Hashkes PJ.4:127–144. Prevention of rheumatic fever in Costa Rica. 73. Bull N Y Acad Med. Rheumatic heart disease epidemiology. Community control of rheumatic heart disease in developing countries: 1 A major public health problem.121:569–572. 97. Benjamin V. Studies of ascorbic acid and rheumatic fever II. Lundin SR. 1928. 98. Mohs E. 105. Pediatr Rheumatol Online J. Forier E. Honikman LH.26:461–467. Chin WA. Orsmond GS.97(6 Pt 2):984–988. 2008. Test of prophylactic and therapeutic action of ascorbic acid. Rheumatic fever and rheumatic heart disease in children in Guyana. Childhood acute rheumatic fever in Greece: experience of the past 18 years. Rodriguez R. Oxygen therapy in acute rheumatic carditis in children. Experience of a ­Wyoming County streptococcal control project. 83. 101(847 Pt 2):410–411. 1984. Rheumatic fever in the U.S. 90. The treatment of acute rheumatism by salicin. Br Med J. Br Med J. 92. Can Med Assoc J. 118. and aspirin.R. Am Heart J. 88. Schultz MP. Changes in the patterns of disease after the epidemiological transition in health in Chile. Cisternas FA.15:385–391.224: 1593–1597. Wang JK. 1971. 1876. 1989. Amezcua J. Rikin T. Maclagan T. Rheumatic fever in Micronesia. Suraya S. Robinson RD Jr. Hassell TA. Ann Rheum Dis. Lancet. 2000. 1995.19:135–140. Pelajo CF. 1969. Rheumatic fever following streptococcal vaccination. Colorado’s high-risk low-socioeconomic region in 1960. Paz JA. Annegers JF. Harel L. Bull Pan Am Health Organ. JAMA. 1950. 2001. Incidence of rheumatic fever in Ceylon. de Oliveira SK. Koshi G. 1980. 1994. Gordis L. 76. 114. Wu FF.80:71–72. Modern trends in acute rheumatism. Pediatr Neurol.92:113–120. Hall P. Marques-Dias MJ. Rheumatic fever and rheumatic heart disease in Barbados: detection and prophylaxis. Clinical Epidemiology 2011:3 Epidemiology of rheumatic fever 94. 1974. 1992. 1994. Adherence to secondary prophylaxis and disease recurrence in 536 Brazilian children with rheumatic fever. 89. Lue HC. 1971. Clinical trials of succinates and of heparin in rheumatic fever.1:555–574. 2006. 10-year educational programme aimed at rheumatic fever in two French Caribbean islands. Longstaffe S.66:379–388. et al. Wu YN. Maclagan T. 1972. Golden R. Rheumatic fever in ­Rochester. Pediatrics. Rheumatic fever and rheumatic heart disease in the western Pacific region. 91.Dovepress 70. et al.18:544–547. 93. Am J Epidemiol.107:383–384. J Pediatr.316:421–427. Morton WE. Report of three cases. De Silva S. 100. Lichty JA. 111. Abbasi AS. American Heart Association. Bach JF. Wrigley F. Massell Dovepress 81 . Three. 75. Med J Aust. 106. 107. 1988 (Technical Report Series No. Giannoulia-Karantana A. Cardiovasc J Afr. 117. 110. Papadopoulou A. 82.2:251–254. Prevalence of heart disease in school children of Karachi. Mayo Clin Proc. Chile. Noah PK. Am J Cardiol. 103. 1961.8:22.2:789–791. 115. Karrison T. Establishment of a rheumatic heart disease registry in Taipei: an early appraisal. 112. Acute rheumatic fever in children. 1979. 78. 1992. Kawakita S.18: 389–396. 84. Dueñas A. Michael JG. 3:387–389. et al. 81. 96.143:399–401.99: 273–280. Szilagyi N. Randomized double-blind study with prednisone in Sydenham’s chorea. Minnesota. 95. Rev Med Chil. 101. Falanruw L. Postl B. Arch Dis Child. Bailen-Rose F. Medicine (Baltimore). 1988. Lancet. 74. Lue HC. Stuart KL. 85.207: 1115–1119. Resurgence of acute rheumatic fever in the intermountain area of the United States. Jpn Circ J. Glazebrook AJ.16:509–518. West J Med. JAMA. Trends in acute rheumatic fever. 1956. Demographic factors and the incidence of acute attacks. Uziel Y. Prevalence survey for chronic rheumatic heart disease and rheumatic fever in northern India. Quesney F.148: 546–550. 1969. Wu MH. 1972. 1996. 116. 104. 1988. Papadopoulos G. 102.34:336–345. Quinn RW. 2006.. et  al. Hwang BT. Ali Syed S. Rheumatic fever in Western Fiji: the female ­preponderence.21: 645–654. Massell BF. 1876. 1986.versus four-week administration of benzathine penicillin G: effects on incidence of streptococcal infections and recurrences of rheumatic fever.84:856. Hashkes PJ. The treatment of rheumatic carditis: a review and meta-analysis. Koshi G. J Pediatr. Can J Public Health. 1996. cortisone. Lopez-Benitez JM. Siner M. Br Heart J. 1973. Blásquez J. 71.74: 1–12. J Chronic Dis. 1981. 2003. J Trop Pediatr. Rheumatic fever in native children in Manitoba. Acute rheumatic fever in the southeastern metropolitan area of Santiago. Amezcua J. Rheumatic fever and rheumatic heart disease in rural South Indian children. Nicolle L. West Indian Med J. Renwick S. J Pediatr.

1990. Bisno AL. Situation épidémiologique du rhumatisme articulaire aigu en Algérie 2005. McBride WJ.16:561–568. Acute rheumatic fever in Indigenous people in North Queensland: some good news at last? Med J Aust. Clark MF.290:2307–2312. 1988. 129.79:549–552. Dovepress Dovepress 141.83:1418–1420. Lancet. Longitudinal study of poststreptococcal disease in Auckland: rheumatic fever. 133. 140. 1987. Chun LT. Yousof AM.htm.39: 361–369. 142. Rheumatic fever in the Nazareth area during the last decade. de la population et de la réforme hospitalière.85:261– 1984. 2010. 1987. Taylor L. An epidemiological study of rheumatic fever and rheumatic heart disease in Lagos. Children with acute rheumatic fever and acute poststreptococcal glomerulonephritis and their families in a subtropical zone: a three-year prospective comparative epidemiological study. Gharagozloo RA. 163.8000 inhabitants in southeast Teheran from 1972–1974. Pattern of acute rheumatic fever in a local teaching hospital. Farwana S. 97:671–673. Med J Malaysia. Mason T. 2007. Reisinder K. 122. Congeni J. Demirçeken F. Rheumatic fever in a developing country in North Africa. Kharrat H.htm. 1981. Lubani M. Alfonso Sánchez JL. 145. Cameroon. Cann MP. Reddy DV. Streptococcal pharyngitis and acute rheumatic fever in Rhode Island. 155. Karademir S.sante. el-Sherbiny AF. multiracial urban community: the Miami-Dade County experience. Kaplan EL. Birnbaum SE. J Epidemiol Community Health. Sive AA. Potter EV. Seckeler MD. Coulehan J. 1984. 1984. Doudin K. Rev Sanid Hig Publica (Madr). 1991. The national programme and the control of rheumatic fever and rheumatic heart disease in two project areas of Thailand. Garst PD. Carceller A. 160. Ueda C. 1991. 131. NZ Med J. Ghafour SY. Talbot RG. 165. Ogunbi O. Brownstein R. Yim GK. Majeed HA. Am J Dis Child.262: 2557–2261.65:17–24.148: 563–567. Currie BJ. Doussary L. 151. Rheumatic fever and rheumatic heart disease among 56. Chun LT.22:798–801. Med J Aust. Cortina Greus P. 1986. Watson DG. South Med J. Med J Aust. Teske DW. An epidemiological survey. 1992. Craenen JM. Clinical presentation of rheumatic fever in an endemic area. 136. Khan N. 124.97:630–634. Acute rheumatic fever in West Virginia. et al. 162. 152. Ghavamian P. Ann Saudi Med.164:720–725. Khuffash FA. Rheumatic fever in children and adolescents in Hawaii. N Z Med J.33:215–222. Carapetis JR. Wong E. glomerulonephritis. 1988.95:62–68. S Med J. 2000. Talbot RG.67:5–10. Earle DP. 154. Teziç T. Acta Trop. González Arraez JI. Acute rheumatic fever and rheumatic heart disease on the Navajo reservation. 2010. 1989.144:179–184. et al. 130. Omar A. Ministère de la santé. Carapetis JR.141:730–733.14:e226–e229. Acute rheumatic fever in Mississippi: a survey of hospitalized cases. Bousnina S.192: 581–584. 137. Isr Med Assoc J. Taylor LR. 1979. AJDC. McDonald M. Chase NA. Norton RE. J Chronic Dis. South Med J. Dodd A.dovepress. 138:476–478. Clinical Epidemiology 2011:3 . 135. Acute rheumatic fever in Tunisia. East Afr Med J. 128.50:125–130. Serotypes of group A streptococci associated with rheumatic fever. Yusuf AR. Cumulative incidence of rheumatic fever in an endemic region: a guide to the susceptibility of the population? Epidemiol Infect.366:155–168. Wilson NJ. et al. Khuffash FA. Sindhavanonda K. Fisher M. 1980. 1964 to 1973. NZ Med J.85:323–325. 1996. Epidemiology of acute rheumatic fever in a multiethnic. 1989.32:68–71. Daneshpajooh M. 2010. A resurgence of acute rheumatic fever in a Mid-South children’s hospital. West J Med. Congeni B. 143. Acute rheumatic fever in Kuwait: the declining incidence. 121. Trans Am Clin Climatol Assoc. 82 submit your manuscript | www. Hepner SI. Flight RJ. Rheumatic fever in the Hamilton health district: a nine year prospective study. Reddy DV. Acute rheumatic fever and rheumatic heart disease in the top end of Australia’s Northern Territory. NZ Med J. Ferguson GW.2:433–437. Erdem G. Odio A. 1983. The incidence of acute rheumatic fever in a suburban area of Los Angeles – a ten-year study. Kopecký A. Majeed HA. Barton LL. Faich GA. The return of acute rheumatic fever in young adults. Hanna JN.83:862–865. Wheller JJ. Rhoads GG. Ahmed I. Rheumatic heart disease in childhood: comparative study between Japan and Thailand. Epidemiological course of rheumatic fever and rheumatic heart disease in Spain (1951–1986). Clin Pediatr (Phila). 161. Accessed August 20. 1976. 101(847 Pt 2):396–398. 147.Seckeler and Hoke 119. 1978. et al. Shultz JM. 2010. Saliba WR. Shaltout A. http://www. 126. Miró J. Miles M. J Infect Dis. Vongprateep C. http://www. 146. 153. de la population et de la réforme hospitalière. Rubin E.97:675–678. Acute rheumatic fever: 27 year experience from the Montreal’s pediatric tertiary care centers.176–179. Nishioka K. 144. Rheumatic fever and rheumatic heart disease at the Rotorua Hospital 1971–1982. 1991. J Pediatr.26:1158–1159. Atalay S. The natural history of acute rheumatic fever in Kuwait: a prospective six year follow-up report. JAMA. Yamamoto LG. 1986. W V Med J. Rizzo C. Acta Paediatr. Resurgence of acute rheumatic fever. Rheumatic fever and rheumatic heart disease in the Hamilton health district: I. Acute rheumatic fever. Martin D. NZ Med J. 125.418:121–123. Chun LT. Recent increase in incidence of acute rheumatic fever in southern West Virginia. Dharmasakti D.101(847 Pt 2):406–408. Incidence of acute rheumatic fever: a suburban community hospital experience during the 1970s. Papadimos TJ. Grant S. Schwartz RH. Ministère de la santé. Kechrid A. 134. 1988. Acute rheumatic fever in American Samoa. 149.51:206–211. Meli J.101(847 Pt 2): 408–410. 2010. epidemiology and M typing 1981–86. Oldfield EC 3rd. 1997. Yamamoto LG. Demircin G. Hefelfinger DC. Wabitsch KR. Lennon D. 1976. Purchas SH. Int J Epidemiol. Tapiero B. Hawaii Med J. 139. JAMA. 120. Carapetis JR. Occurrence and prevention of rheumatic fever among ethnic groups of Kujala G. 157.95:455–457. Habib GS. Rheumatic diseases in patients attending a clinic at a referral hospital in Yaounde. Outbreak of acute rheumatic fever in northeast Ohio.164:146–149. Finau SA. 1989.sante. Taikato MR. Kriz P. 159. 1988. Adv Exp Med Biol. 2000.124:239–244. Holmberg SD. Reddy V. Wallace MR. ­Suliman MA. 1994. Cortés Vizcaíno C. The persistent challenge of rheumatic fever in the Northern Mariana Islands. Accessed August 20. 1992. 2007. Acute rheumatic fever in children in the Ankara area in 1990–1992 and comparison with a previous study in 1980–1989. 1984. 164. Tuua A. Eckerd JM. Streptococcal infections. Pediatr Infect Dis J. 1962–77. Powell KE. 1983. 2007.13:56–59. 132. Majeed HA.84:404–409. Sipahi T. 138. 148. Rheumatic heart disease and school screening: initiatives at an isolated hospital in Tonga. 1993. Ntsiba H. Currie BJ. 156.74: 553–557. 123. 1995. Phornphvtkul C. Int J Infect Dis. Resurgence of acute rheumatic fever in west Alabama. Arch Dis Child. 158. Sreenivasan VV. Arch Intern Med. Hosier DM. et al. Singwe-Ngandeu M.87:224–234. Situation épidémiologique du rhumatisme articulaire aigu en Algérie 2004. Jpn Circ J. Mader R. Smeyers Durá P. McJunkin JE. Ketheesan N. Acute rheumatic fever in Hawaii: 1966 to 1988. Mathews JD. Pediatrics. Leggiadro RJ. Myers LK. Sharda DC. Fadahunsi HO. Public Health Rep. Wolff DR.151:133–136. The Northland rheumatic fever register. Cesk Pediatr. Poon-King T.44:533–535. acute nephritis and rheumatic fever in Trinidad – further observations. Kopecká B. 2005. 150.111.43:487–489. NZ Med J. 1987. 1987. An Pediatr (Barc). Okuda R. Mori C. Farwana SS. Mohsen Z.

Tjipta GD. Bull Épi Hebdom.14:1407–1413. 182.18:295–299. A study of clinical manifestations of acute rheumatic fever. East Mediterr Health J. J Paediatr Child Health. Kim NS. Seo IJ. Nelson B. Madden S. Kaplan EL.16: 99–108. Steer A. 2000. Kohler LA. Pac Health Dialog.27: 49–54. Karaaslan S. 168.57:471–474. Al-Hakim F. Paediatr Indones. 191. Incidence and clinical manifestations of rheumatic fever: a 6 year community-based survey. 195. 44:564–571. 21:86–92. Pyles LA. 207. Guel L. et al. Thi Nhi C. Chin J Cardiol. Estudo da prevalência da febre reumática. WHO Chron. Chen C-L. Rhumatisme articulaire aigu chez l’enfant: à propos de 169 cas. laboratory and echocardiographic profile of acute rheumatic fever in Nepali children. Hoffman TM. Grover A. 2005–2007. Siregar AA. Shrestha NK. Acute rheumatic fever and rheumatic heart disease in Fiji: prospective surveillance. Hallorímsson J. Colquhoun S. Anderson FL. Kado J. Federated States of Micronesia. Rheumatic heart disease among Omani schoolchildren. 2007. Bolz D. World Health Organ. Epidemiology of acute rheumatic fever in New Zealand 1996–2005. 1996. Epidemiology of diseases caused by Streptococcus pyogenes in Serbia during a nine-year period (1991–1999). et  al.26:94–97. 176. editor. 202. Rhumatisme articulaire aigu. Celiker A.69:821–833. et al. Epidemiological survey of rheumatic heart disease among school children in the Shimla Hills of northern India: prevalence and risk factors. Prevalence of the rheumatic diseases in urban Vietnam: a WHO-ILAR COPCORD study. Clinical Epidemiology 2011:3 Epidemiology of rheumatic fever 186. 1979. 209. Obeid M. Halliog˘lu O. The natural history of ­rheumatic fever and rheumatic heart disease in the Orient. 1994. Benevolenskaia LI. 2007. 171. Jaffer A. 204. Ann Trop Paediatr. 187. Chen SL. Peyramond D. Cohen R. Pediatr Cardiol. Boucot I. Alik T. Einzig S. 1979. 1998. Schlemmer B . Clinical. Cuboni G. Dovepress 83 . NZ Med J. Ediciones Díaz de Santos. Silva MO. Shakya U. Huang ZD. Abud Mendoza C. 172. Truckenbrodt H. 1979.6:642–646. Hajar HA. Underdiagnosis of acute rheumatic fever in primary care settings in a developing country. 1975. Opavski N. submit your manuscript | www. Rhumatisme articulaire aigu: résultats d’une enquête nationale (1995–1997). 190.21:119–122. 192. Rheumatic fever and rheumatic heart disease in Samoa.83:633–638. Pediatr Int. Wei H. Le Hello S. Update on acute rheumatic fever: it still exists in remote communities. et al. et al. Rheumatism in the Russian Federation: statistic and reality. et  al. Vestn Ross Akad Med Nauk. 183. Medan (1983–1985).11: 21–24. Kafetzis DA. 2003. 1997. An autopsy study.34:533–535. 1996. Chen X. Vinker S. 2009. Ozkutlu S. Ayoub EM. Atatoa-Carr P. Rao XX. Epidemiology of rheumatic fever and rheumatic heart disease in a rural community in northern India. 208. A pilot study for the primary prevention of rheumatic fever in Kosrae. Reddy KS. 177. Shulman ST. Ranin L. Djukic S. Najada A. Reisli I. Isr Med Assoc J. Vijaykumar M. 2003. 205. Ben Meriem C. Hasab AA. Reyes PA. Chauvet J. 206. 2010.55:475–478. 2008. Hammami S. Eur J Clin Microbiol Infect Dis. Turkey.190:133–135. Sichuan Da Xue Xue Bao Yi Xue Ban. Indian J Med Res. Rheumatic fever and rheumatic heart diseases in Fiji: a review from the surveillance system (1996–2000). Eltohami EA. en milieu scolaire en Côte d’Ivoire. Cen YC. Pac Health Dialog. Group A streptococcal antibodies in subjects with or without rheumatic fever in areas with high or low incidences of rheumatic fever. 179. Prevalence of rheumatic heart disease in Delhi school children. 1999.30:2252–2256. 2007. Cordera González de Cosío F. Jpn Heart J. Incidence and prevalence of juvenile arthritis in an urban population of southern Germany: a prospective study. Khriesat I. Kelly L. Geneva. Elhayany A. Childhood acute rheumatic fever: a comparison of recent resurgence areas to cases in West Virginia. Bertrand E. Arch Cardiol Mex. 1973. Rayamajhi A. Clinical and microbial characteristics of invasive Streptococcus pyogenes disease in New Caledonia. Lennon DR. Hörmann A. Zohar E. Acute rheumatic fever in Konya. J Pédia Puér. Portier H. Clin Diagn Lab Immunol. advantageous socioeconomic conditions. Chantzi FM. 203. Bell A. 1997.71:127–135. Naim M. 185. J Rheumatol. Von Koskull S. Venugopal K. Strasser T. An epidemiologic investigation of acute rheumatic fever and rheumatic heart disease among students aged 5–18 in west area of Sichuan Province. Vougiouka O. 193. Karagöz T. Liapi G.121:96–105.93:260–263. Angiology. a region in Oceania with a high incidence of acute rheumatic fever. Turk J Pediatr. Van Hung N. Balian AA. Quirós AB. Acta Pathol Microbiol Scand A. School of Medicine. Incidence of ­rheumatic fever and prevalence of rheumatic heart disease in India. 2001. Ganguly NK. Baumann F.48:526–530. Trop Med Int Health.50:62–67. Rotta J. Ngoc An T. Jenney AW. Suppl 119:155–159. Jatene AD. Mikati M.42:71–75. W V Med J. Etude de la prévalence des cardiopathies.13:39–47. 71:59–66.13:31–38. Hayek P. Gharzeddine W. Erkul I. 2008. 2006. Joint WHO/ISFC meeting on rheumatic fever/rheumatic heart disease control with emphasis on primary prevention. 178. 2001. Lue H-C. An updated epidemiologic survey of acute rheumatic fever among school-age children in China.48: 481–489. Chronic rheumatic valvular heart disease. Ahluwalia SK. University of North Sumatera/Dr. Finau SA. Minh Hoa TT. 7–9 September 1994. 2003. 2010. Cardiovasc J Afr. Parks T.3:17–23. The control of rheumatic fever and rheumatic heart disease: an outline of WHO activities.10:886–890.12:78–81. Rhodes LA. Rev Saude Publica. Riyami AM. 2005. Wahi PL. Yum MG. Acute rheumatic fever in the Waikato District Health Board region of New Zealand: 1998–2004. Darmawan J. et al. Soto López ME. Holle R. 175. Padmavati S. Narula J. Med J Aust. Bull World Health Organ.60: 940–945. 2004. Ann Rheum Dis. Can Fam Phys. 2nd ed. Acute rheumatic fever in Jordanian children. 180. Halim S. 2006. Incidence and clinical profile of acute rheumatic fever in Greece. 1979. Finatti AA. 2009. notamment rhumatismales.9: 981–987. Karaye KM. 198. Viali S. Coly M. 2006.27:169–177.11:116–123.dovepress. 197. J Clin Microbiol. Tyndall A. Sharma D. Kaplan EL. Thakur JS. Vaidya NK. Pac Health Dialog. Fiebre reumática. Rheumatic fever in the 5-year period of 1994–1999 at 2 hospitals in San Luis Potosi and Mexico D. 196. 1994:1159–1166. Indian J Med Res. Bull World Health Organ. Steer AC. 200. Mijac V.encore actuel en Suisse? Forum Médical Suisse. Pediatriá. Folger GM Jr. Ozer S.12:1–5.24:68–70. Prevalence and pattern of rheumatic heart disease in the Nigerian savannah: an echocardiographic study. 167. 170. J Korean Pediatr Cardiol Soc. Carapetis J. 1989. Jeong EY. J Epidemiol ­Community Health.F.43:221–228. 201. et al. 2003. Jun BJ. 2009. 173. 2005. Cuboni HD. 2000. 184.20: 237–252.13:1–6. Ghédira L. Estrada L. Baker M. 194. Acute rheumatic fever in an Arabian Gulf country – effect of climate. Doloy A.Dovepress 166. Rheumatic fever in children: a 15-year experience in a developing country.47:120–124. Hoffman R. 1997.29: 64–71. Borodo MM. Pirngadi Hospital. Rheumatic fever and rheumatic heart disease at the Department of Child Health. 1993. Abu-Haweleh A. Bitar FF. Kado J. Oran B. Alehan D.1):1–52. 188. Jaine R. Huang D. Negi PC. Iyengar SD. Neal WA. 1994 (WHO/CVD 94. East Med Health J. In: MH Rodríguez. 2010. Int J Cardiol. Childhood acute rheumatic fever in Ankara. Dhawan A. 169. 2008. Olivier C. Zhang M. Folomeeva OM. Bertolami V. Grigoriadou G. 174. Anand IS. Dbaibo GS. Turkey. 199. and access to medical care. 189. Sani MU.

Int J Cardiol. et al. et  al. 2007. Tahir M. Meta-analysis of trials of streptococcal throat treatment programs to prevent rheumatic fever. March DR. Effectiveness of comprehensive-care programs in preventing rheumatic fever. Augestad KM. Kumar R. McNeil SA. health policies & economic evaluations. 213. Pandey MR.119:1456–1459. Carapetis JR.40:31–37. Cardiol Young.54:54–58. Mostafa Zaman M. Forsgren L. et  al. risk factor modification. 1999. Saudi Arabia. Epidemiology of rheumatic heart disease in black shcoolchildren of Dovepress Clinical Epidemiology 2011:3 . ­Johannesburg. Okoko A. A prospective study of 66 patients. Arroll B. Zaher SR. 1995. 233. 244. Rheumatic heart disease and school screening: initiatives at an isolated hospital in Tonga. Rheumatic heart disease in school children in Western District. 230. 1981. prevention.90:57–59. 243. Cumulative incidence of rheumatic fever in an endemic region: a guide to the susceptibility of the population? Epidemiol Infect. 2008.135: 236–238. Gombet T. Porteous J. Ganguly NK. Alurkar V. Pasha O. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Saatova GM. Chen ATH. McLaren MJ. Martyshov S. Indian Heart J. Clinical Epidemiology Publish your work in this journal Clinical Epidemiology is an international. 2009. Taylor L. 2009. J Indian Med Assoc. Antia AU. Circulation. Trop Doct. Hawkins DM. Schwankhaus JD. Chin J Cardiol. Indian Heart J. Regmi PR. 1975. screening. et al. Mathews JD. Steer AC. Finau SA. Mendis S.18:62–69. Buadromo EM. Survey of rheumatic heart disease in schoolchildren of Kinshasa town. al-Sweliem AA. identification of risk factors and screening procedures to develop optimal preventative initiatives and programs. which is all easy to use. translational medicine. et  al.63:287–294. 1992.46:258–263. J Epidemiol. Raobijaona H. Juma H.120:709–713. Omurzakova NA. Thaplia A.16:S68. Médecine d’Afrique Noire. 240.3:474–478. et al. Huang ZD. 1981. some of the time: susceptibility to acute rheumatic fever. 1998. N Engl J Med. Am J Dis Child. 214. Br Med J. Rheumatic fever and rheumatic heart disease in school children of Kathmandu city. Currie BJ. 211. 2009. treatment. Anabwani GM. Le ­rhumatisme articulaire aigu (RAA) a antananarivo (Madagascar). Rhumatisme articulaire aigu et cardiopathies rhumatismales de l’enfant a Brazzaville. Brazil. 1998.45:686–689. Langley JM. risk & safety of medical interventions. Sherif AA. Carapetis JR. 223. Rheumatic fever and rheumatic heart disease in Northwest Russia.12:79–83. Carapetis JR. prognosis.49: 518–520. Prevalence of cardiac murmurs and acute rheumatic fever in schoolchildren in rural Nepal. 1973. 2005. 1992. Longo-Mbenza B.35:160–161. Lie M. et al. Ann Intern Med. Prevalence of rheumatic heart disease among school children in Addis Ababa. Lim HS. 218. Les Cardiopathies rhumatismales en milieu scolaire à Brazzaville. Epidemiology of rheumatic heart disease among primary school children in western Kenya.289:331–335. Robins-Browne R. peer-reviewed. 241. Mayosi BM. Ekstedt J. Voumbo Y. 227. Perera K. 2009. Current status of rheumatic heart disease in China. 1992. Kathmandu Univ Med J. The high burden of rheumatic heart disease found on autopsy in Fiji. Int J Cardiol. 1994. Amoa AB. Aggarwal AK. 2000. Bryant PA. Tekle-Haimanot R. Singh PI. Foederov B. Al-Sekait MA. An epidemiological survey of rheumatic fever and rheumatic heart disease in Sahafa Town. Mbika Cardorelle A. 2008. 1990. High incidence of rheumatic fever and rheumatic heart disease in the republics of Central Asia.4: 222–227. A community-based rheumatic fever/rheumatic heart disease cohort: twelve-year experience.119:742–753. de Castilho SRT. 239. Bayekula M.73:233–254.23:249–252. 238. Yamao Y. 237. Kerdemelidis M. 1999. Is primary prevention of rheumatic fever the missing link in the control of rheumatic heart disease in Africa? Circulation. Karthikeyan G. systematic Dovepress 228. J R Soc Health. Martyshova K. 219. Meira ZMA. Dovepress reviews. Nasser M. Rizvi SF. Prevalence of chronic rheumatic heart disease in Chinese adults. Zhimin W. Med Trop. Halperin SA.76:601–605.148: 563–567. 222. Lennon D. et al. 242. 217. Gupta ML. Egypt: a prospective epidemiological study. 2005. Anyanwu CH.Seckeler and Hoke 210. Cheng PMY. Kimbally-Kaky G.124:239–244. Koornhof HJ.33:8–13.121:77. Trop Geogr Med. A study of rheumatic heart disease and rheumatic fever in a defined population in Sri Lanka. Ahmed J. Abdel-Moula AM.65:331–334.110:15–16. 1998. Submit your manuscript here: http://www. Int J Cardiol. Parihar A.80:152–155. Okoroma EO. Gupta CD. 2004. Clin Infect Dis. Samad A. Preventing rheumatic heart disease in developing countries. 1998. 216. Elhag M. 2006. 215. et al. Cen YC. 212. Cardiology. 236. 2006. Ceylon J Med Sci. Gordis L.41:1114–1122. Heart Lung Circ. Kundi A. Ramachandran U. Oli K.68: 603–605. 226. J Egypt Public Health Assoc.26:98–100. Pediatr Infect Dis J. Epidemiology of rheumatic and congenital heart diseases in school children. Oli K. Ali E. 234. Some of the people. Samberkar PN. open access journal focusing on disease and drug epidemiology. Ibrahim-Khalil S. The manuscript management system is completely online and includes a very quick and fair peer-review system.18:204–208. Khan MA. Nepal. epidemiology & biostatical methods. 225. 231. Muita AK. Monzur Hassan MM. Kassem AS. Rheumatic fever in Nigerian children. 1997.dovepress.28:e259–e264. et  al. et al. 1998. Jaiyesimi F. Prevalence of rheumatic fever in children from a public high school in Belo Horizonte. Moyen G. Barros MVL. Yubao Z. Med J Aust 1988. 229. Ihenacho IN. Soliman EZ. 232. Lei S.107:356–359. 1989. 1999. 221.46:477–479. Andrianjanaka JC. Specific topics include: diagnosis. Cardiac disease patterns in northern Malawi: ­epidemiologic transition perspective. 235. Rao XX. Sudan. Gupta I. Curtis N. Status of rheumatic heart disease in rural Pakistan. Arch Brasilian Cardiol. Prevalence of rheumatic fever and rheumatic heart disease in rural Bangladesh. Rakotorimanana 84 submit your manuscript | www. 2008. East Afr Med J. 224. Sallam SA.dovepress.90: 394–399. Prevalence of rheumatic heart disease among school children in Alexandria. Pattern of cardiac diseases in children in Pokhara. Tidsskr Nor Laegeforen. Médecine d’Afrique Noire. Int J Rheum Dis. 2002. 245. Ngiyulu R. Mandil AM. J Epidemiol Community Health. 220. Raizada A. Heart. Childhood rheumatic heart disease in Nigeria. evaluation of guidelines. Rheumatic heart disease prevalence among schoolchildren of an Ethiopian rural town.